日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase I Study of (131)I-Metaiodobenzylguanidine With Dinutuximab ± Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A New Approaches to Neuroblastoma Therapy Trial.

(131)I-间碘苄胍联合Dinutuximab±Vorinostat治疗复发或难治性神经母细胞瘤患者的I期研究:神经母细胞瘤治疗新方法试验

Cash Thomas, Marachelian Araz, DuBois Steven G, Chi Yueh-Yun, Baregamyan Anahit, Groshen Susan G, Jonus Hunter C, Shamirian Anasheh, Crowley Mary, Goodarzian Fariba, Acharya Patricia T, Pawel Bruce, Erbe Amy K, Shahi Ankita, Zaborek Jen, Kennedy Eleanor, Asgharzadeh Shahab, Villablanca Judith G, Pinto Navin, Weiss Brian D, Mosse Yael P, Desai Ami V, Macy Margaret E, Granger Meaghan, Vo Kieuhoa T, Sondel Paul M, Matthay Katherine K, Park Julie R, Goldsmith Kelly C

Lorlatinib with or without chemotherapy in ALK-driven refractory/relapsed neuroblastoma: phase 1 trial results

劳拉替尼联合或不联合化疗治疗ALK驱动的难治性/复发性神经母细胞瘤:1期临床试验结果

Goldsmith, Kelly C; Park, Julie R; Kayser, Kimberly; Malvar, Jemily; Chi, Yueh-Yun; Groshen, Susan G; Villablanca, Judith G; Krytska, Kateryna; Lai, Lillian M; Acharya, Patricia T; Goodarzian, Fariba; Pawel, Bruce; Shimada, Hiroyuki; Ghazarian, Susan; States, Lisa; Marshall, Lynley; Chesler, Louis; Granger, Meaghan; Desai, Ami V; Mody, Rajen; Morgenstern, Daniel A; Shusterman, Suzanne; Macy, Margaret E; Pinto, Navin; Schleiermacher, Gudrun; Vo, Kieuhoa; Thurm, Holger C; Chen, Joseph; Liyanage, Marlon; Peltz, Gerson; Matthay, Katherine K; Berko, Esther R; Maris, John M; Marachelian, Araz; Mossé, Yael P

Early-phase clinical trial eligibility and response evaluation criteria for refractory, relapsed, or progressive neuroblastoma: A consensus statement from the National Cancer Institute Clinical Trials Planning Meeting

难治性、复发性或进展性神经母细胞瘤早期临床试验入组标准和疗效评价标准:美国国家癌症研究所临床试验规划会议共识声明

Park, Julie R; Villablanca, Judith G; Hero, Barbara; Kushner, Brian H; Wheatley, Keith; Beiske, Klaus H; Ladenstein, Ruth L; Baruchel, Sylvain; Macy, Margaret E; Moreno, Lucas; Seibel, Nita L; Pearson, Andrew D; Matthay, Katherine K; Valteau-Couanet, Dominique

Expression of neuroblastoma-related genes in bone marrow at end of high-risk neuroblastoma therapy

高危神经母细胞瘤治疗结束时骨髓中神经母细胞瘤相关基因的表达

Asgharzadeh, Shahab; Marachelian, Araz; Villablanca, Judith G; Liu, Wei Yao; Kennedy, Rebekah; Sposto, Richard; Naranjo, Arlene; Tenney, Sheena; Yu, Alice L; Ozkaynak, M Fevzi; Sondel, Paul M; Park, Julie R; Seeger, Robert C

Randomized Phase II Trial of MIBG Versus MIBG, Vincristine, and Irinotecan Versus MIBG and Vorinostat for Patients With Relapsed or Refractory Neuroblastoma: A Report From NANT Consortium

一项针对复发或难治性神经母细胞瘤患者的随机II期试验:MIBG对比MIBG、长春新碱和伊立替康对比MIBG和伏立诺他:来自NANT联盟的报告

DuBois, Steven G; Granger, M Meaghan; Groshen, Susan; Tsao-Wei, Denice; Ji, Lingyun; Shamirian, Anasheh; Czarnecki, Scarlett; Goodarzian, Fariba; Berkovich, Rachel; Shimada, Hiroyuki; Villablanca, Judith G; Vo, Kieuhoa T; Pinto, Navin; Mosse, Yael P; Maris, John M; Shusterman, Suzanne; Cohn, Susan L; Goldsmith, Kelly C; Weiss, Brian; Yanik, Gregory A; Twist, Clare J; Irwin, Meredith S; Haas-Kogan, Daphne A; Park, Julie R; Marachelian, Araz; Matthay, Katherine K

A safety and feasibility trial of (131) I-MIBG in newly diagnosed high-risk neuroblastoma: A Children's Oncology Group study

一项关于 (131)I-MIBG 治疗新诊断高危神经母细胞瘤的安全性和可行性试验:儿童肿瘤协作组研究

Weiss, Brian D; Yanik, Gregory; Naranjo, Arlene; Zhang, Fan F; Fitzgerald, Wendy; Shulkin, Barry L; Parisi, Marguerite T; Russell, Heidi; Grupp, Stephan; Pater, Luke; Mattei, Peter; Mosse, Yael; Lai, Hollie A; Jarzembowski, Jason A; Shimada, Hiroyuki; Villablanca, Judith G; Giller, Roger; Bagatell, Rochelle; Park, Julie R; Matthay, Katherine K

A single-arm study of systemic and sub-Tenon chemotherapy for Groups C and D intraocular retinoblastoma: A Children's Oncology Group study (ARET 0231)

一项针对 C 组和 D 组眼内视网膜母细胞瘤的全身和球结膜下化疗的单臂研究:儿童肿瘤协作组研究 (ARET 0231)

Jubran, Rima F; Villablanca, Judith G; Krailo, Mark; Piao, Jin; Huang, Li; Murphree, A Linn; O'Brien, Joan; Gombos, Dan; Shields, Carol L; Meadows, Anna; Chintagumpala, Murali

Role of the extent of prophylactic regional lymph node radiotherapy on survival in high-risk neuroblastoma: A report from the COG A3973 study

预防性区域淋巴结放疗范围对高危神经母细胞瘤患者生存率的影响:来自COG A3973研究的报告

Braunstein, Steve E; London, Wendy B; Kreissman, Susan G; Villablanca, Judith G; Davidoff, Andrew M; DeSantes, Kenneth; Castleberry, Robert P; Murray, Kevin; Diller, Lisa; Matthay, Katherine; Cohn, Susan L; Shulkin, Barry; von Allmen, Daniel; Parisi, Marguerite T; Van Ryn, Collin; Park, Julie R; La Quaglia, Michael P; Haas-Kogan, Daphne A

Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial

伏立诺他联合异维A酸治疗难治性/复发性神经母细胞瘤患者的I期研究:神经母细胞瘤治疗新方法(NANT)试验

Pinto, Navin; DuBois, Steven G; Marachelian, Araz; Diede, Scott J; Taraseviciute, Agne; Glade Bender, Julia L; Tsao-Wei, Denice; Groshen, Susan G; Reid, Joel M; Haas-Kogan, Daphne A; Reynolds, C Patrick; Kang, Min H; Irwin, Meredith S; Macy, Margaret E; Villablanca, Judith G; Matthay, Katherine K; Park, Julie R

Predictors of response, progression-free survival, and overall survival using NANT Response Criteria (v1.0) in relapsed and refractory high-risk neuroblastoma

使用 NANT 反应标准 (v1.0) 预测复发和难治性高危神经母细胞瘤的疗效、无进展生存期和总生存期

Villablanca, Judith G; Ji, Lingyun; Shapira-Lewinson, Adi; Marachelian, Araz; Shimada, Hiroyuki; Hawkins, Randall A; Pampaloni, Miguel; Lai, Hollie; Goodarzian, Fariba; Sposto, Richard; Park, Julie R; Matthay, Katherine K